Ilkka Liikanen

1.3k total citations
37 papers, 985 citations indexed

About

Ilkka Liikanen is a scholar working on Oncology, Genetics and Molecular Biology. According to data from OpenAlex, Ilkka Liikanen has authored 37 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 22 papers in Genetics and 14 papers in Molecular Biology. Recurrent topics in Ilkka Liikanen's work include Virus-based gene therapy research (22 papers), CAR-T cell therapy research (22 papers) and Viral Infectious Diseases and Gene Expression in Insects (9 papers). Ilkka Liikanen is often cited by papers focused on Virus-based gene therapy research (22 papers), CAR-T cell therapy research (22 papers) and Viral Infectious Diseases and Gene Expression in Insects (9 papers). Ilkka Liikanen collaborates with scholars based in Finland, Germany and United States. Ilkka Liikanen's co-authors include Akseli Hemminki, Anna Kanerva, Minna Oksanen, Timo Joensuu, Anniina Koski, Otto Hemminki, Vincenzo Cerullo, Iulia Diaconu, Sari Pesonen and Raita Heiskanen and has published in prestigious journals such as Journal of Clinical Investigation, Clinical Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Ilkka Liikanen

31 papers receiving 964 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ilkka Liikanen Finland 17 657 654 367 256 167 37 985
David Mansfield United Kingdom 18 505 0.8× 519 0.8× 279 0.8× 195 0.8× 146 0.9× 58 1.0k
Edward P. Cohen United States 22 524 0.8× 250 0.4× 708 1.9× 912 3.6× 130 0.8× 117 1.7k
Sari Pesonen Finland 16 629 1.0× 734 1.1× 448 1.2× 213 0.8× 206 1.2× 24 947
William D. Hunter United States 11 808 1.2× 1.6k 2.4× 886 2.4× 148 0.6× 154 0.9× 16 1.9k
Timo Joensuu Finland 18 668 1.0× 716 1.1× 367 1.0× 190 0.7× 176 1.1× 27 893
Padma Sampath United States 16 597 0.9× 517 0.8× 280 0.8× 327 1.3× 112 0.7× 19 843
Lotta Kangasniemi Finland 16 685 1.0× 840 1.3× 542 1.5× 145 0.6× 243 1.5× 24 1.0k
João M. Santos Finland 18 823 1.3× 691 1.1× 336 0.9× 366 1.4× 212 1.3× 39 1.1k
Joan Kyula United Kingdom 21 576 0.9× 443 0.7× 460 1.3× 161 0.6× 142 0.9× 33 1.0k
Judith Roth Germany 15 738 1.1× 269 0.4× 824 2.2× 88 0.3× 286 1.7× 21 1.2k

Countries citing papers authored by Ilkka Liikanen

Since Specialization
Citations

This map shows the geographic impact of Ilkka Liikanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilkka Liikanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilkka Liikanen more than expected).

Fields of papers citing papers by Ilkka Liikanen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilkka Liikanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilkka Liikanen. The network helps show where Ilkka Liikanen may publish in the future.

Co-authorship network of co-authors of Ilkka Liikanen

This figure shows the co-authorship network connecting the top 25 collaborators of Ilkka Liikanen. A scholar is included among the top collaborators of Ilkka Liikanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilkka Liikanen. Ilkka Liikanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liikanen, Ilkka, Dafne C.A. Quixabeira, Otto Hemminki, et al.. (2022). Oncolytic adenovirus decreases the proportion of TIM-3+ subset of tumor-infiltrating CD8+ T cells with correlation to improved survival in patients with cancer. Journal for ImmunoTherapy of Cancer. 10(2). e003490–e003490. 18 indexed citations
2.
3.
Hemminki, Otto, Minna Oksanen, Ilkka Liikanen, et al.. (2018). Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. Molecular Therapy — Oncolytics. 9. 41–50. 7 indexed citations
4.
Liikanen, Ilkka, Siri Tähtinen, Kilian Guse, et al.. (2016). Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer. Molecular Cancer Therapeutics. 15(9). 2259–2269. 30 indexed citations
5.
Liikanen, Ilkka, Anniina Koski, Raita Heiskanen, et al.. (2016). Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. Molecular Therapy. 24(7). 1323–1332. 30 indexed citations
6.
Bramante, Simona, Anniina Koski, Ilkka Liikanen, et al.. (2015). Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. OncoImmunology. 5(2). e1078057–e1078057. 36 indexed citations
7.
Liikanen, Ilkka, Anniina Koski, Otto Hemminki, et al.. (2015). Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. OncoImmunology. 4(3). e989771–e989771. 53 indexed citations
8.
Hemminki, Otto, Suvi Parviainen, Juuso Juhila, et al.. (2015). Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. Oncotarget. 6(6). 4467–4481. 69 indexed citations
9.
Liikanen, Ilkka, Juuso Juhila, Riku Turkki, et al.. (2015). Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus. Molecular Therapy. 24(1). 175–183. 25 indexed citations
10.
Kanerva, Anna, Anniina Koski, Ilkka Liikanen, et al.. (2014). Case–Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors. Molecular Therapy. 23(2). 321–329. 12 indexed citations
11.
Kanerva, Anna, Petri Nokisalmi, Iulia Diaconu, et al.. (2013). Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Clinical Cancer Research. 19(10). 2734–2744. 144 indexed citations
12.
Hirvinen, Mari, Raita Heiskanen, Minna Oksanen, et al.. (2013). Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment. Journal of Translational Medicine. 11(1). 193–193. 15 indexed citations
13.
Liikanen, Ilkka, Vladia Monsurrò, Laura Ahtiainen, et al.. (2011). Induction of Interferon Pathways Mediates In Vivo Resistance to Oncolytic Adenovirus. Molecular Therapy. 19(10). 1858–1866. 39 indexed citations
14.
Koski, Anniina, Mari Raki, Petri Nokisalmi, et al.. (2011). Verapamil Results in Increased Blood Levels of Oncolytic Adenovirus in Treatment of Patients With Advanced Cancer. Molecular Therapy. 20(1). 221–229. 28 indexed citations
15.
Dias, João D., Ilkka Liikanen, Kilian Guse, et al.. (2010). Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1. Clinical Cancer Research. 16(9). 2540–2549. 36 indexed citations
16.
Liikanen, Ilkka. (2010). From Post-Modern Visions to Multi-Scale Study of Bordering : Recent Trends in European Study of Borders and Border Areas. Hokkaido University Collection of Scholarly and Academic Papers (Hokkaido University). 1(1). 17–28. 4 indexed citations
17.
Liikanen, Ilkka, João D. Dias, Petri Nokisalmi, et al.. (2010). Adenoviral E4orf3 and E4orf6 Proteins, But Not E1B55K, Increase Killing of Cancer Cells by Radiotherapy in vivo. International Journal of Radiation Oncology*Biology*Physics. 78(4). 1201–1209. 3 indexed citations
18.
Scott, James W. & Ilkka Liikanen. (2010). Civil Society and the ‘Neighbourhood’ — Europeanization through Cross‐Border Cooperation?. Journal of European Integration. 32(5). 423–438. 21 indexed citations
19.
Dias, João D., Kilian Guse, Petri Nokisalmi, et al.. (2009). Multimodal approach using oncolytic adenovirus, cetuximab, chemotherapy and radiotherapy in HNSCC low passage tumour cell cultures. European Journal of Cancer. 46(3). 625–635. 25 indexed citations
20.
Liikanen, Ilkka. (1995). Fennomania ja kansa : joukkojärjestäytymisen läpimurto ja Suomalaisen puolueen synty. Doria (University of Helsinki). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Mansfield Breakdown of academic impact, for papers by Edward P. Cohen Breakdown of academic impact, for papers by Sari Pesonen Breakdown of academic impact, for papers by William D. Hunter Breakdown of academic impact, for papers by Timo Joensuu Breakdown of academic impact, for papers by Padma Sampath Breakdown of academic impact, for papers by Lotta Kangasniemi Breakdown of academic impact, for papers by João M. Santos Breakdown of academic impact, for papers by Joan Kyula Breakdown of academic impact, for papers by Judith Roth
Rankless by CCL
2026